Plus Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recognized grant revenue of $1.4 million for the third quarter, a slight decrease from $1.5 million in the same period last year. For the nine months ended September 30, 2025, total grant revenue was $3.8 million, down from $4.4 million in the prior year. The company incurred an operating loss of $4.5 million for the quarter, compared to a loss of $2.9 million in the same quarter of 2024, and a total net loss of $16.7 million for the nine months, up from $9.1 million in the previous year.
The financial performance reflects a notable increase in operating expenses, which totaled $5.9 million for the third quarter, compared to $5.3 million in the same period last year. Research and development expenses decreased to $2.4 million from $2.9 million year-over-year, while general and administrative expenses rose to $3.4 million from $2.4 million, primarily due to increased compensation and professional fees. The company’s accumulated deficit reached $510.2 million as of September 30, 2025.
In terms of strategic developments, Plus Therapeutics has made significant strides in its clinical programs and partnerships. The company is preparing to launch its CNSide Test, a diagnostic tool for cancer patients, with plans to reintroduce it to the U.S. market in the fourth quarter of 2025. Additionally, Plus Therapeutics has entered into a national agreement with UnitedHealthcare, which will provide coverage for the CNSide Test to over 51 million people. The company also acquired a cerebrospinal fluid cancer diagnostic portfolio from Biocept, enhancing its capabilities in cancer diagnostics.
Operationally, Plus Therapeutics has seen an increase in its cash position, with cash and cash equivalents rising to $13.3 million from $76,000 at the end of the previous fiscal year. The company’s total current assets increased to $17.6 million, while current liabilities decreased to $13.6 million. The company has also been actively raising capital, with net cash provided by financing activities amounting to $27.5 million for the nine months ended September 30, 2025, primarily from the Lincoln Park Purchase Agreement and the March 2025 Private Placement.
Looking ahead, Plus Therapeutics faces challenges in maintaining compliance with Nasdaq listing requirements, particularly regarding stockholder equity and share price. The company has until November 12, 2025, to regain compliance with the minimum bid price requirement. Management has indicated that ongoing capital raises will be necessary to support clinical development and operational needs, emphasizing the importance of securing additional funding to sustain its growth trajectory and operational viability.
About PLUS THERAPEUTICS, INC.
Plus Therapeutics, Inc. develops targeted radiotherapeutics and medical devices for central nervous system and solid organ cancers. Its core platform delivers high-dose radiation directly to tumors, aiming to improve safety and efficacy over traditional therapies. The company’s key products include REYOBIQ and CNSide diagnostics, targeting brain, leptomeningeal, and pediatric cancers, with a focus on innovative, minimally invasive treatments and companion diagnostic tools.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.